KR102902295B1 - 피라졸로피리딘 유도체 및 이의 용도 - Google Patents
피라졸로피리딘 유도체 및 이의 용도Info
- Publication number
- KR102902295B1 KR102902295B1 KR1020237034868A KR20237034868A KR102902295B1 KR 102902295 B1 KR102902295 B1 KR 102902295B1 KR 1020237034868 A KR1020237034868 A KR 1020237034868A KR 20237034868 A KR20237034868 A KR 20237034868A KR 102902295 B1 KR102902295 B1 KR 102902295B1
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- cycloalkyl
- compound
- delete delete
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163161139P | 2021-03-15 | 2021-03-15 | |
| US63/161,139 | 2021-03-15 | ||
| US202163164130P | 2021-03-22 | 2021-03-22 | |
| US63/164,130 | 2021-03-22 | ||
| PCT/IB2022/052281 WO2022195454A1 (en) | 2021-03-15 | 2022-03-14 | Pyrazolopyridine derivatives and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20230156766A KR20230156766A (ko) | 2023-11-14 |
| KR102902295B1 true KR102902295B1 (ko) | 2025-12-23 |
Family
ID=80819999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237034868A Active KR102902295B1 (ko) | 2021-03-15 | 2022-03-14 | 피라졸로피리딘 유도체 및 이의 용도 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US11787785B2 (https=) |
| EP (1) | EP4308562A1 (https=) |
| JP (2) | JP7659648B2 (https=) |
| KR (1) | KR102902295B1 (https=) |
| AU (2) | AU2022239950B2 (https=) |
| CA (1) | CA3208951A1 (https=) |
| CL (1) | CL2023002726A1 (https=) |
| CO (1) | CO2023013486A2 (https=) |
| CR (1) | CR20230486A (https=) |
| DO (1) | DOP2023000188A (https=) |
| EC (1) | ECSP23076800A (https=) |
| IL (1) | IL305931A (https=) |
| JO (1) | JOP20230218A1 (https=) |
| MX (1) | MX2023010827A (https=) |
| PE (1) | PE20242203A1 (https=) |
| PY (1) | PY2217419A (https=) |
| UY (1) | UY39671A (https=) |
| WO (1) | WO2022195454A1 (https=) |
| ZA (1) | ZA202307290B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PY2217419A (es) | 2021-03-15 | 2022-09-27 | Novartis Ag | Derivados de pirazolopiridina y sus usos |
| WO2022195355A1 (en) * | 2021-03-15 | 2022-09-22 | Novartis Ag | Benzisoxazole derivatives and uses thereof |
| EP4612128A4 (en) | 2022-11-04 | 2025-09-10 | Bristol Myers Squibb Co | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEMOGLOBINOPATHIES |
| WO2024255810A1 (en) * | 2023-06-15 | 2024-12-19 | Hangzhou Glubio Pharmaceutical Co., Ltd | Dihydropyrimidine-2, 4 (1h, 3h) -dione-containing polycyclic derivatives and pharmaceutical composition thereof, preparation method thereof and use thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007513164A (ja) | 2003-12-02 | 2007-05-24 | セルジーン・コーポレーション | 異常ヘモグロビン症及び貧血症の治療及び管理のための方法及び組成物 |
| WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
| JP2020531498A (ja) | 2017-08-23 | 2020-11-05 | ノバルティス アーゲー | ３−（１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン誘導体及びその使用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| EP1604988A1 (en) | 2004-05-18 | 2005-12-14 | Sanofi-Aventis Deutschland GmbH | Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals |
| KR101608259B1 (ko) | 2008-04-28 | 2016-04-01 | 교린 세이야꾸 가부시키 가이샤 | 시클로펜틸아크릴산아미드 유도체 |
| EP2165707A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| PL3202460T3 (pl) * | 2010-02-11 | 2019-12-31 | Celgene Corporation | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| CN104619709B (zh) | 2012-07-13 | 2016-11-09 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的咪唑并吡啶衍生物 |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| JP2020009513A (ja) * | 2018-07-10 | 2020-01-16 | キオクシア株式会社 | メモリシステム |
| AR116109A1 (es) * | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CN120574283A (zh) | 2019-04-05 | 2025-09-02 | 凯麦拉医疗公司 | Stat降解剂和其用途 |
| EP3969458A4 (en) | 2019-05-13 | 2023-05-17 | Borah, Inc. | CHEMICAL COMPOUNDS |
| PH12022551482A1 (en) | 2019-12-18 | 2023-11-29 | Novartis Ag | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| KR20220138399A (ko) | 2020-02-04 | 2022-10-12 | 스팅레이 테라퓨릭스, 인크. | 엑토뉴클레오티드 피로포스파타제/포스포디에스테라제 1(enpp1)의 억제제 및 이의 사용 방법 |
| US20230089530A1 (en) | 2020-02-09 | 2023-03-23 | Newave Pharmaceutical Inc. | Quinuclidinone analogues as anticancer agents |
| PY2217419A (es) | 2021-03-15 | 2022-09-27 | Novartis Ag | Derivados de pirazolopiridina y sus usos |
-
2022
- 2022-03-11 PY PY202202217419A patent/PY2217419A/es unknown
- 2022-03-11 UY UY0001039671A patent/UY39671A/es unknown
- 2022-03-14 CR CR20230486A patent/CR20230486A/es unknown
- 2022-03-14 KR KR1020237034868A patent/KR102902295B1/ko active Active
- 2022-03-14 CA CA3208951A patent/CA3208951A1/en active Pending
- 2022-03-14 JP JP2023556474A patent/JP7659648B2/ja active Active
- 2022-03-14 IL IL305931A patent/IL305931A/en unknown
- 2022-03-14 AU AU2022239950A patent/AU2022239950B2/en active Active
- 2022-03-14 WO PCT/IB2022/052281 patent/WO2022195454A1/en not_active Ceased
- 2022-03-14 MX MX2023010827A patent/MX2023010827A/es unknown
- 2022-03-14 PE PE2023002595A patent/PE20242203A1/es unknown
- 2022-03-14 US US17/693,759 patent/US11787785B2/en active Active
- 2022-03-14 EP EP22711643.1A patent/EP4308562A1/en active Pending
-
2023
- 2023-07-21 ZA ZA2023/07290A patent/ZA202307290B/en unknown
- 2023-09-01 US US18/460,428 patent/US12172984B2/en active Active
- 2023-09-13 DO DO2023000188A patent/DOP2023000188A/es unknown
- 2023-09-13 CL CL2023002726A patent/CL2023002726A1/es unknown
- 2023-09-14 JO JOJO/P/2023/0218A patent/JOP20230218A1/ar unknown
- 2023-10-12 CO CONC2023/0013486A patent/CO2023013486A2/es unknown
- 2023-10-12 EC ECSENADI202376800A patent/ECSP23076800A/es unknown
-
2024
- 2024-09-06 US US18/826,887 patent/US12252482B2/en active Active
- 2024-11-06 US US18/939,314 patent/US20250282762A1/en active Pending
- 2024-12-09 AU AU2024278210A patent/AU2024278210B2/en active Active
-
2025
- 2025-03-28 JP JP2025056015A patent/JP2025106341A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007513164A (ja) | 2003-12-02 | 2007-05-24 | セルジーン・コーポレーション | 異常ヘモグロビン症及び貧血症の治療及び管理のための方法及び組成物 |
| JP2020531498A (ja) | 2017-08-23 | 2020-11-05 | ノバルティス アーゲー | ３−（１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン誘導体及びその使用 |
| WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4076650B1 (en) | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | |
| KR102902295B1 (ko) | 피라졸로피리딘 유도체 및 이의 용도 | |
| US12103919B2 (en) | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | |
| US20250276964A1 (en) | Benzisoxazole Derivatives and Uses thereof | |
| CN116802182A (zh) | 吡唑并吡啶衍生物及其用途 | |
| CN116940571A (zh) | 苯并异噁唑衍生物及其用途 | |
| BR112023018542B1 (pt) | Derivados de pirazolopiridina, e composição e combinação farmacêuticas | |
| BR122025004894A2 (pt) | Derivados de pirazolopiridina, seus usos, composição e combinação farmacêuticas, e kit | |
| EA051403B1 (ru) | Производные пиразолопиридина и пути их применения | |
| NZ723817B2 (en) | Cyclopropylamines as lsd1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |